Takahiro Kinoshita

Takahiro Kinoshita

Auto-generated profile, based on publicly available information

Takahiro Kinoshita

Department of Gastric Surgery, National Cancer Center Hospital East, Kashiwa, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Cancer Cell
Verified
Journal Article
Closed access
SKShogo Kumagai
Shogo Kumagai
SKShohei Koyama
Shohei Koyama
KIKota Itahashi
Kota Itahashi
TTTokiyoshi Tanegashima
Tokiyoshi Tanegashima
YLYi-Tzu Lin
Yi-Tzu Lin
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa

1 July 2020 in Immunity
Verified
Journal Article
Closed access
SKShogo Kumagai
Shogo Kumagai
YTYosuke Togashi
Yosuke Togashi
CSChika Sakai
Chika Sakai
AKAkihito Kawazoe
Akihito Kawazoe
MKMasahito Kawazu
Masahito Kawazu
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa

1 January 2015 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
TKT Kinoshita
T Kinoshita
ASA Saiura
A Saiura
MEM Esaki
M Esaki
HSH Sakamoto
H Sakamoto
TYT Yamanaka
T Yamanaka
Background: The efficacy of surgical resection for gastric cancer liver metastases (GCLMs) is currently debated. Hitherto, no large-scale clinical studies have been conducted. Methods: This retrospective multicentre study analysed a database of consecutive patients with either synchronous or metachronous metastases who underwent surgical R0 resection for GCLM between 1990 and 2010. Clinical data were collected from five cancer centres in Japan. Survival curves were assessed, and clinical parameters were evaluated to identify predictors of prognosis. Results: A total of 256 patients were enrolled. The mean(s.d.) number of hepatic tumours resected was 2·0(2·4). The surgical mortality rate was 1·6 per cent. Median follow-up was 65 (range 1–261) months. Recurrences were detected in 192 patients (75·0 per cent). The median interval from hepatic resection to recurrence was 7 (range 1–72) months, and the dominant site of recurrence was the liver (72·4 per cent). Actuarial 1-, 3- and 5-year overall and recurrence-free survival rates were 77·3, 41·9 and 31·1 per cent, and 43·6, 32·4 and 30·1 per cent, respectively. Median overall and recurrence-free survival times were 31·1 and 9·4 months respectively. Multivariable analysis identified serosal invasion of the primary gastric cancer (hazard ratio (HR) 1·50; P = 0·012), three or more liver metastases (HR 2·33; P < 0·001) and liver tumour diameter at least 5 cm (HR 1·62; P = 0·005) as independent predictors of poor survival. Conclusion: Clinically resectable GCLM is rare, but strict and careful patient selection can lead to long-term survival following R0 surgical resection.

25 June 2018 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
HLHeli Liu
Heli Liu
TKTakahiro Kinoshita
Takahiro Kinoshita
ATAkiko Tonouchi
Akiko Tonouchi
AKAkio Kaito
Akio Kaito
MTMasanori Tokunaga
Masanori Tokunaga

27 June 2012 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TKTakahiro Kinoshita
Takahiro Kinoshita
NGNaoto Gotohda
Naoto Gotohda
YKYuichiro Kato
Yuichiro Kato
STShinichiro Takahashi
Shinichiro Takahashi
MKMasaru Konishi
Masaru Konishi

2 December 2015 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MWMasahiro Watanabe
Masahiro Watanabe
TKTakahiro Kinoshita
Takahiro Kinoshita
NENaoki Enomoto
Naoki Enomoto
HSHidehito Shibasaki
Hidehito Shibasaki
TNToshirou Nishida
Toshirou Nishida